Point72 Asset Management
NERV icon

Point72 Asset Management’s Minerva Neurosciences NERV Stock Holding History

Point72 Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$231K – 1699
2022
Q3 		$231K Buy
+25,000
New +$148K ﹤0.01% 1255
2020
Q1 		– Sell
-28,125
Closed -$1.6M – 980
2019
Q4 		$1.6M Buy
28,125
+7,746
+38% +$342K 0.01% 648
2019
Q3 		$1.26M Buy
+20,379
New +$1.15M 0.01% 655
2019
Q1 		– Sell
-17,268
Closed -$931K – 1156
2018
Q4 		$931K Buy
17,268
+2,232
+15% +$163K ﹤0.01% 814
2018
Q3 		$1.51M Buy
+15,036
New +$1.13M 0.01% 793

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's NERV Position: Q4 2022 in Review

Point72 Asset Management sold out of Minerva Neurosciences (NERV) in Q4 2022, closing a stake of 25,000 shares — an estimated $231K sold.

Point72 Asset Management first reported a position in NERV in Q3 2018 and held it in 5 quarters. The position peaked at $1.6M in Q4 2019. 19 funds tracked by Wall St. Rank hold NERV as of Q4 2022.

  • Point72 Asset Management reported no remaining Minerva Neurosciences position as of Q4 2022 after selling out during the quarter.
  • Point72 Asset Management sold 25,000 Minerva Neurosciences shares in Q4 2022, an estimated $231K.
  • Point72 Asset Management first reported a position in Minerva Neurosciences in Q3 2018 and held it in 5 quarters.
  • Point72 Asset Management's Minerva Neurosciences position peaked at $1.6M in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2022.

Based on Point72 Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.